📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Concord Biotech Q3 Revenue Up 14% YoY to ₹278 Cr; PAT Dips 8.5% on Exceptional Costs
Concord Biotech reported a 13.9% YoY increase in revenue from operations to ₹27,813 lakhs for Q3 FY26. However, Net Profit (PAT) declined by 8.5% YoY to ₹6,778 lakhs, primarily impacted by a one-time exceptional charge of ₹327.54 lakhs related to new labour code regulations. On a sequential basis, the company showed recovery with revenue and PAT growing 12.6% and 7.8% respectively compared to Q2 FY26. The board also strengthened its leadership by appointing Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer.
Key Highlights
Revenue from operations grew 13.9% YoY to ₹27,813.39 lakhs in Q3 FY26 compared to ₹24,422.02 lakhs in Q3 FY25.
Net Profit (PAT) for the quarter stood at ₹6,778.27 lakhs, a decline from ₹7,408.88 lakhs in the corresponding quarter last year.
Recognized an exceptional item of ₹327.54 lakhs due to the statutory impact of new labour codes on employee benefit obligations.
9-month PAT for FY26 shows a significant decline to ₹17,324.46 lakhs from ₹23,102.69 lakhs in the same period last year.
Appointed Mr. Paritosh Trivedi as Company Secretary and Compliance Officer effective February 11, 2026.
💼 Action for Investors
Investors should monitor the margin pressure as PAT has declined despite healthy revenue growth. The significant year-to-date profit lag compared to the previous fiscal suggests a cautious outlook until bottom-line growth stabilizes.
CONCOR Signs MoU with Vizhinjam International Seaport for New Container Freight Station
CONCOR has signed a non-binding Memorandum of Understanding (MoU) with Vizhinjam International Seaport Ltd (VISL) to develop a Container Freight Station (CFS) in Kerala. Under the agreement, VISL will provide the land while both parties will jointly develop infrastructure including customs-bonded areas, warehouses, and container handling yards. This strategic move positions CONCOR at a key upcoming deep-water transshipment hub, enhancing its multimodal logistics capabilities in South India. The collaboration is aimed at improving cargo handling efficiencies and supporting the growth of India's EXIM trade.
Key Highlights
MoU signed on February 23, 2026, for a new CFS near Vizhinjam International Seaport, Thiruvananthapuram.
VISL, a Kerala Government undertaking, will provide land for the project on mutually agreed terms.
The facility will feature customs-bonded areas, warehouses, and specialized import-export cargo handling facilities.
Strategic focus on leveraging Vizhinjam's status as a global maritime gateway for rail-led multimodal logistics.
Both parties will enter a subsequent definitive agreement to frame detailed terms and conditions.
💼 Action for Investors
This is a positive development for long-term growth as it secures CONCOR's presence at a critical transshipment hub. Investors should monitor the transition from a non-binding MoU to a definitive agreement for clarity on capital expenditure and timelines.
Concord Biotech Q3 FY26 Revenue Grows 14% to ₹278 Cr; API Segment Surges 24%
Concord Biotech reported a recovery in Q3 FY26 with revenue growing 14% YoY to ₹278 crores, though 9-month revenue remains 5% lower at ₹729 crores due to H1 disruptions. The API business was a major driver this quarter, growing 24% to ₹219 crores, while the formulation segment saw a decline. Reported EBITDA margins stood at 35.6%, impacted by start-up costs for the new injectable facility; however, core margins remain healthy at 40%. Management expects a return to historical growth levels in FY27 as regulatory hurdles clear and the injectable business scales toward its ₹600 crore peak potential.
Key Highlights
Q3 FY26 revenue increased 14% YoY to ₹278 crores, led by strong API performance of ₹219 crores.
Adjusted EBITDA margins (excluding start-up and US subsidiary costs) remained stable at 40%.
The new injectable facility received WHO GMP certification, targeting a peak revenue of ₹600 crores.
9-month PAT stood at ₹64 crores, impacted by ₹3 crores in new labor code provisions and lower other income.
Company remains debt-free with cash and bank balances of ₹350 crores as of December 31, 2025.
💼 Action for Investors
Investors should focus on the scale-up of the injectable facility and the resumption of Middle East tenders as primary growth drivers for FY27. The stock is a recovery candidate as temporary headwinds from H1 FY26, such as CDSCO delays and tariff uncertainties, have largely been resolved.
Concord Biotech Q3 Revenue Up 14% to Rs 278 Cr; EBITDA Margins Impacted by Expansion Costs
Concord Biotech reported a 14% YoY revenue growth in Q3FY26, reaching Rs 278 crore, primarily driven by a 24% surge in the API segment. However, PAT declined by 16% YoY to Rs 64 crore due to commercialization expenses for the new injectable facility and setup costs for its US subsidiary, Stellon Biotech. EBITDA margins compressed to 35.6% from 40.1% a year ago, though normalized margins remain healthy at approximately 40%. The company achieved a significant milestone by receiving WHO-GMP certification for its injectable plant, paving the way for domestic market entry.
Key Highlights
Q3FY26 Revenue grew 14% YoY to Rs 278 crore, led by robust 24% growth in the API segment.
EBITDA margins stood at 35.6%, impacted by one-time setup costs; normalized margins are at ~40%.
Received WHO-GMP certification for Unit 4 (Injectable facility), enabling domestic brand launches.
Established US subsidiary Stellon Biotech Inc. to create a direct commercial footprint in the US market.
Appointed Raviraj Karia as the new Chief Financial Officer (CFO) with 23+ years of experience.
💼 Action for Investors
Investors should monitor the ramp-up of the new injectable facility and the performance of the US subsidiary, as these are the primary drivers for future growth despite current margin pressure. The long-term outlook remains positive due to specialized fermentation capabilities and global expansion.
Concord Biotech Approves Q3 FY26 Results; Appoints New Company Secretary
Concord Biotech's Board of Directors approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The statutory auditors, BSR & Co. LLP, issued a limited review report with an unmodified opinion, suggesting no major accounting concerns. Additionally, the company appointed Mr. Paritosh Trivedi as the new Company Secretary and Compliance Officer effective February 11, 2026. This appointment fills a key managerial personnel (KMP) role to oversee corporate governance and regulatory filings.
Key Highlights
Board approved unaudited financial results for the third quarter and nine months ended December 31, 2025.
Statutory auditors M/s. BSR & Co. LLP issued a Limited Review Report with an Unmodified Opinion.
Mr. Paritosh Trivedi appointed as Company Secretary, Compliance Officer, and Nodal Officer.
The new appointee brings 5 years of experience in corporate compliance across Textile, IT, and FMCG sectors.
The board meeting concluded at 6:22 P.M. on February 11, 2026.
💼 Action for Investors
Investors should examine the detailed financial tables once published to assess revenue and margin performance for Q3. The appointment of a new compliance officer is a routine administrative update and does not impact the company's fundamental value.
CONCOR Q3 FY26: Record Throughput, Dividend Declared, and FY29 Revenue Target of ₹15,000 Cr
CONCOR reported its highest-ever nine-month throughput of 4.15 million TEUs, marking an 11% growth driven by both EXIM and Domestic segments. While PAT was flattish due to a ₹68 crore increase in depreciation and higher Land License Fees (LLF), operating margins improved by 100 bps to 31.2%. The company has aggressively raised its FY26 CAPEX budget to ₹1,060 crore and set a bold revenue target of ₹15,000 crore by FY29, anticipating a massive boost from the Western Dedicated Freight Corridor (DFC) completion in March 2026.
Key Highlights
Achieved record throughput of 4.15 million TEUs with EXIM up 10% and Domestic up 13%.
Declared an interim dividend of ₹3.40 per share, bringing total FY26 dividends to ₹7.60 (152%).
Rail freight margins expanded by 200 bps to 27.7%, while operating margins reached 31.2%.
Enhanced FY26 CAPEX budget by 23% to ₹1,060 crore to support infrastructure and fleet expansion.
Management projects FY29 targets of ₹15,000 crore revenue and 10 million TEUs throughput.
💼 Action for Investors
Investors should view the flattish PAT as a temporary accounting adjustment and focus on the robust margin expansion and volume growth. The upcoming Western DFC connectivity in March 2026 remains the primary catalyst for long-term re-rating.
CONCOR Signs MOU for Bharat Container Shipping Line JV with 30% Stake
CONCOR has signed a Memorandum of Understanding with the Shipping Corporation of India (SCI) and several port authorities to form a new Joint Venture named Bharat Container Shipping Line (BCSL). CONCOR and SCI will each hold a 30% stake, while Sagarmala Finance Corporation will hold 20%, and various port authorities will hold the remaining 20%. The JV aims to acquire and operate container vessels to provide end-to-end logistics solutions for EXIM and coastal trade. This strategic move allows CONCOR to integrate sea-based transportation with its existing land-based rail and terminal infrastructure.
Key Highlights
CONCOR and SCI to hold 30% equity each in the proposed JV company BCSL
Sagarmala Finance Corporation Ltd. (SMFCL) to hold a 20% stake
Port authorities JNPA (10%), VOCPA (5%), and CPA (5%) are the other key partners
JV will focus on acquiring, owning, and leasing container vessels and related assets
Aims to provide integrated end-to-end logistics by combining port, land, and sea services
💼 Action for Investors
Investors should monitor this development as a significant vertical integration move that could improve CONCOR's long-term margins and market share. Watch for future disclosures regarding the initial capital infusion and the timeline for vessel acquisition.
CONCOR Declares Rs 3.40 Interim Dividend; Reports Q3 FY26 Financial Results
Container Corporation of India (CONCOR) has declared its third interim dividend of Rs 3.40 per share (68% of face value) for FY 2025-26, amounting to Rs 258.95 crores. The company reported its financial results for the quarter ended December 31, 2025, alongside a significant change in accounting estimates for its LNG fleet. Specifically, the useful life of LNG Trucks and Trailers has been extended from 8 to 15 years, which will reduce depreciation expenses. The Land License Fee (LLF) remains an area of focus as final terms with Indian Railways are still pending.
Key Highlights
Declared 3rd interim dividend of Rs 3.40 per equity share (68% of face value).
Total dividend payout of Rs 258.95 crores with a record date set for February 9, 2026.
Revised useful life of LNG Trucks and Trailers from 8 years to 15 years, lowering depreciation costs.
Land License Fee (LLF) payments to Indian Railways continue based on the 2022 Master Circular assessment.
Consolidated results incorporate performance from 4 subsidiaries and 11 jointly controlled entities.
💼 Action for Investors
Investors should track the record date of February 9, 2026, to qualify for the interim dividend. The change in depreciation estimates will provide a tailwind to margins, though the final resolution of Land License Fees remains a long-term watch item.
CONCOR Declares 3rd Interim Dividend of Rs 3.40 Per Share; Sets Record Date for Feb 9, 2026
Container Corporation of India (CONCOR) has declared its third interim dividend for FY 2025-26 at 68% of face value, which translates to Rs 3.40 per equity share. The total dividend payout is estimated at Rs 258.95 crores. The company has fixed February 9, 2026, as the record date to determine shareholder eligibility for this payment. Alongside the dividend, the company released its Q3 FY26 financial results and noted a significant change in accounting estimates regarding the useful life of LNG trucks.
Key Highlights
Declared 3rd interim dividend of Rs 3.40 per equity share (68% of face value of Rs 5 each)
Total dividend payout for this interim declaration amounts to Rs 258.95 crores
Record date for dividend eligibility is fixed as February 9, 2026
Dividend payment or dispatch to shareholders will commence on or after February 16, 2026
Accounting estimate for useful life of LNG Trucks & Trailers revised from 8 years to 15 years
💼 Action for Investors
Investors looking to benefit from the dividend must hold the shares before the record date of February 9, 2026. Long-term investors should also monitor the impact of revised depreciation costs on future profitability.
CONCOR Declares 3rd Interim Dividend of ₹3.40 per Share for FY 2025-26
Container Corporation of India (CONCOR) has declared its third interim dividend of ₹3.40 per equity share for the financial year 2025-26, representing 68% of the face value. The total dividend payout is estimated at ₹258.95 crores, with the record date set for February 9, 2026. Alongside the dividend, the company approved its Q3 FY26 financial results and announced a change in the accounting estimate for the useful life of LNG trucks from 8 to 15 years. Investors should remain aware of the ongoing uncertainty regarding Land License Fees (LLF) payable to Indian Railways.
Key Highlights
Declared 3rd interim dividend of ₹3.40 per share (68% of face value)
Total dividend payout amounting to ₹258.95 crores
Record date for dividend eligibility fixed as February 9, 2026
Accounting estimate for LNG Trucks & Trailers useful life increased from 8 to 15 years
Dividend payment to be completed within 30 days of declaration
💼 Action for Investors
Investors interested in the dividend should ensure they hold the stock before the record date of February 9, 2026. Monitor the impact of revised depreciation and Land License Fee developments on future profitability.
CONCOR Declares 3rd Interim Dividend of Rs 3.40 per Share for FY 2025-26
The Board of Directors of Container Corporation of India (CONCOR) has declared a third interim dividend of Rs 3.40 per equity share for the financial year 2025-26, representing 68% of the face value. The total dividend payout is estimated at Rs 258.95 crores. The company has fixed February 9, 2026, as the record date for determining shareholder eligibility, with payments expected to commence from February 16, 2026. Alongside the dividend, the company reported its Q3 FY26 results and noted a change in accounting estimates for LNG trucks, extending their useful life to 15 years.
Key Highlights
3rd Interim Dividend declared at Rs 3.40 per equity share (68% of face value)
Total financial outlay for the dividend payout stands at Rs 258.95 crores
Record date for dividend entitlement is fixed as February 9, 2026
Dividend payment to be dispatched to shareholders on or after February 16, 2026
Accounting estimate for LNG Trucks & Trailers revised from 8 years to 15 years, reducing depreciation
💼 Action for Investors
Investors seeking dividend income should ensure they hold the shares before the record date of February 9, 2026. The revision in depreciation estimates for LNG assets may provide a minor positive impact on the bottom line in upcoming quarters.
CONCOR Q3 Results: Board Declares 3rd Interim Dividend of Rs 3.40 Per Share
Container Corporation of India (CONCOR) has announced its financial results for the quarter ended December 31, 2025, alongside a third interim dividend of Rs 3.40 per share. The total dividend payout is estimated at Rs 258.95 crores, with the record date fixed for February 9, 2026. Notably, the company has revised the useful life of its LNG trucks from 8 to 15 years, which will reduce depreciation costs. However, the Land License Fee (LLF) payable to Indian Railways remains a point of emphasis as final terms are still pending.
Key Highlights
Declared 3rd interim dividend of 68% amounting to Rs 3.40 per equity share for FY 2025-26.
Total interim dividend outflow for this tranche stands at Rs 258.95 crores.
Accounting estimate for useful life of LNG Trucks & Trailers increased from 8 to 15 years.
Land License Fee (LLF) assessment remains provisional based on the October 2022 Master Circular.
Record date for dividend eligibility is set for February 9, 2026, with payment starting February 16.
💼 Action for Investors
Investors should track the record date of February 9 to qualify for the dividend. The extension of asset life for LNG trucks will provide a tailwind to earnings through lower depreciation expenses.
CONCOR Reports 10.78% Growth in Total Physical Volumes for Q3 FY26
CONCOR reported a healthy 10.78% year-on-year growth in total physical volumes for the quarter ended December 2025, reaching 14.23 lakh TEUs. The domestic segment outperformed with a 13.43% growth, while the EXIM segment grew by 9.94%. For the nine-month period ended December 2025, total volumes increased by 10.85% to 41.54 lakh TEUs. This consistent double-digit growth indicates strong operational momentum across both international and domestic logistics operations.
Key Highlights
Total throughput for QE Dec-25 rose 10.78% YoY to 14,23,266 TEUs.
Domestic (DOM) volumes saw robust growth of 13.43% YoY, reaching 3,51,121 TEUs.
EXIM volumes increased by 9.94% YoY to 10,72,145 TEUs during the quarter.
Cumulative nine-month (PE Dec-25) total volumes grew 10.85% to 41,54,091 TEUs compared to the previous year.
💼 Action for Investors
Investors should view this volume growth as a positive lead indicator for the upcoming quarterly financial results. The strong performance in the domestic segment is particularly encouraging for long-term growth prospects.
Concord Biotech Appoints Raviraj Karia as CFO; Brings 23+ Years of Pharma Experience
Concord Biotech has appointed Mr. Raviraj Karia as its new Chief Financial Officer, effective December 18, 2025. Mr. Karia is a Chartered Accountant with over 23 years of experience in the pharmaceutical and healthcare sectors, having held leadership roles at Intas Pharmaceuticals and Claris Lifesciences. His expertise spans multi-billion dollar financing, large-scale M&A, and cost-efficiency programs. This strategic appointment is aimed at strengthening the company's financial discipline and governance as it scales.
Key Highlights
Appointment of Mr. Raviraj Karia as CFO and Key Managerial Personnel effective December 18, 2025
Brings over 23 years of experience in pharmaceuticals, healthcare, and private equity sectors
Previously managed multi-billion dollar financing programs and led major outbound pharma acquisitions
Proven track record of reducing borrowing costs by 2-3% annually through financial optimization
Expertise in implementing digital tools like SAP-based MIS and Power BI for financial governance
💼 Action for Investors
Investors should view this as a positive move for corporate governance and financial strategy. Monitor the company's future capital allocation and cost-efficiency metrics under the new leadership.
Concord Biotech Appoints Raviraj Karia as CFO; Brings 23+ Years of Pharma Finance Experience
Concord Biotech Limited has appointed Mr. Raviraj Karia as its Chief Financial Officer (CFO) and Key Managerial Personnel, effective December 18, 2025. Mr. Karia is a Chartered Accountant with over 23 years of extensive experience in the pharmaceutical, healthcare, and clinical research sectors. He has previously held leadership roles at prominent firms such as Intas Pharmaceuticals, Claris Lifesciences, and Shalby Hospitals. His expertise includes managing multi-billion dollar financing programs and executing large-scale outbound acquisitions, which is expected to strengthen the company's financial governance.
Key Highlights
Mr. Raviraj Karia appointed as CFO and Key Managerial Personnel effective December 18, 2025.
Brings over 23 years of experience across pharmaceuticals, healthcare, and private equity sectors.
Proven track record in managing multi-billion dollar financing and reducing borrowing costs by 2-3% annually in previous roles.
Expertise in M&A, having led India’s largest outbound pharma acquisition during his career.
Previous leadership experience at Intas Pharmaceuticals, Sakar Healthcare, and Lambda Therapeutics.
💼 Action for Investors
Investors should view this as a positive step in strengthening the leadership team; monitor the company's financial strategy and capital allocation under the new CFO.